Page 3 - Nasdaq Sttk News Today

Equities research analysts at Citigroup assumed coverage on shares of Shattuck Labs (NASDAQ:STTK – Get Rating) in a report issued on Wednesday, Briefing.com reports. The brokerage set a “buy” rating and a $13.00 price target on the stock. Citigroup’s price target would indicate a potential upside of 354.55% from the company’s current price. Other analysts […]

Shattuck Labs (NASDAQ:STTK – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Zacks.com reports. According to Zacks, “Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of […]

- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - -...

Shattuck Labs (NASDAQ:STTK – Get Rating) announced its quarterly earnings results on Tuesday. The company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.61, MarketWatch Earnings reports. Shares of STTK opened at $4.43 on Wednesday. The company has a market cap of $187.15 million, a P/E ratio of […]